Германия - немски - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

essex pharma gmbh (3084925) - mianserinhydrochlorid - filmtablette - teil 1 - filmtablette; mianserinhydrochlorid (11284) 60 milligramm

Германия - немски - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

essex pharma gmbh (3084925) - mianserinhydrochlorid - filmtablette - teil 1 - filmtablette; mianserinhydrochlorid (11284) 10 milligramm

Германия - немски - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

organon healthcare gmbh (1007295) - finasterid - filmtablette - finasterid (24743) 5 milligramm

Израел - английски - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

Израел - английски - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

Малайзия - английски - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - ethinyloestradiol; desogestrel -

Малайзия - английски - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - desogestrel; ethinyloestradiol -

Малайзия - английски - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

organon malaysia sdn. bhd. - tibolone -

Бразилия - португалски - ANVISA (Agência Nacional de Vigilância Sanitária)

organon farmacÊutica ltda. - prednisona - glicocorticoides sistemicos

Австралия - английски - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.